## NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES DIVISION OF HEALTH BENEFITS DIALYSIS - COVID 19 - VACCINES ADMIN AND MONOCLONAL ANTIBODIES (MAB) ADMIN FEE SCHEDULE

Fee Schedule ONLY For Outpatient Facility Services To Be Billed Under Revenue Code 0771 <a href="https://medicaid.ncdhhs.gov/blog/2022/04/07/special-bulletin-covid-19-243-revised-outpatient-billing-guidance-vaccine-and-monoclonal-antibody">https://medicaid.ncdhhs.gov/blog/2022/04/07/special-bulletin-covid-19-243-revised-outpatient-billing-guidance-vaccine-and-monoclonal-antibody</a>

Last Updated: October 5th 2022

PROCEDURE CODE	PROCEDURE CODE DESCRIPTION	RATE	EFFECTIVE DATE	END DATE	NOTES 1	NOTES 2	NOTES 3	NOTES 4
0001A	Pfizer-BioNTech COVID-19 VaccineAdministration – First Dose	65.00	4/1/2021	12/31/9999				
0001A	Pfizer-BioNTech COVID-19 VaccineAdministration – First Dose	40.00	3/15/2021	3/31/2021				
0001A	Pfizer-BioNTech COVID-19 VaccineAdministration – First Dose	16.94	12/11/2020	3/14/2021				
0002A	Pfizer-BioNTech COVID-19 Vaccine Administration – Second Dose	65.00	4/1/2021	12/31/9999				
0002A	Pfizer-BioNTech COVID-19 Vaccine Administration – Second Dose	40.00	3/15/2021	3/31/2021				
0002A	Pfizer-BioNTech COVID-19 Vaccine Administration – Second Dose	28.39	12/11/2020	3/14/2021				
0003A	Pfizer-BioNTech COVID-19 Vaccine Administration – Third Dose	65.00	08/12/221	12/31/9999				
0004A	Pfizer-BioNTech COVID-19 Vaccine Administration – Booster	65.00	9/22/2021	12/31/9999				
0011A	Moderna COVID-19 Vaccine Administration – First Dose	65.00	4/1/2021	12/31/9999				
0011A	Moderna COVID-19 Vaccine Administration – First Dose	40.00	3/15/2021	3/31/2021				
0011A	Moderna COVID-19 Vaccine Administration – First Dose	16.94	12/18/2020	3/14/2021				
0012A	Moderna COVID-19 Vaccine Administration – Second Dose	65.00	4/1/2021	12/31/9999				
0012A	Moderna COVID-19 Vaccine Administration – Second Dose	40.00	3/15/2021	3/31/2021				
0012A	Moderna COVID-19 Vaccine Administration – Second Dose	16.94	12/18/2020	3/14/2021				
0013A	Moderna COVID-19 Vaccine Administration – Third Dose	65.00	8/12/2021	12/31/9999				
0031A	Janssen (Johnson & Johnson) COVID- 19 Vaccine Administration - First Dose	65.00	4/1/2021	12/31/9999				
0031A	Janssen (Johnson & Johnson) COVID- 19 Vaccine Administration - First Dose	40.00	3/15/2021	3/31/2021				
0031A	Janssen (Johnson & Johnson) COVID- 19 Vaccine Administration - First Dose	28.39	2/27/2021	3/14/2021				
0034A	Janssen (Johnson & Johnson) COVID- 19 Vaccine Administration - Booster	65.00	10/20/2021	12/31/9999				
0051A	Pfizer-BioNTech COVID-19 Vaccine - Pre-Diluted (Gray CAP)_ Administration - First dose	65.00	1/10/2022	12/31/9999				
0052A	Pfizer-BioNTech COVID-19 Vaccine - Pre-Diluted (Gray CAP) Administration - Second dose	65.00	1/10/2022	12/31/9999				
0053A	Pfizer-BioNTech COVID-19 Vaccine - Pre-Diluted (Gray CAP) Administration - Third dose	65.00	1/10/2022	12/31/9999				
0054A	Pfizer-BioNTech COVID-19 Vaccine - Pre-Diluted (Gray CAP)_ Administration - Booster	65.00	1/10/2022	12/31/9999				
0064A	Moderna COVID-19 Vaccine (Low Dose) Administration - Booster	65.00	10/20/221	12/31/9999				
0071A	Pfizer-BioNTech COVID-19 Pediatric Vaccine - Administration - First dose	65.00	10/29/2021	12/31/9999				
0072A	Pfizer-BioNTech COVID-19 Pediatric Vaccine - Administration - Second dose	65.00	10/29/2021	12/31/9999				
0073A	Pfizer-BioNTech COVID-19 Pediatric Vaccine - Administration - Third dose	65.00	1/3/2022	12/31/9999				
0074A	Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Booster.	65.00	5/19/2022	12/31/9999				
0081A	First dose	65.00	2/15/2022	12/31/9999				
000271	Second dose	65.00	2/15/2022	12/31/9999				
0083A	Third dose	65.00	6/7/2022	12/31/9999				
	Pfizer-BioNTech Covid-19 Vaccine, Bivalent (Ready to Use) Administration - Booster	65.00	8/31/2022	12/31/9999	Added 10/5/2022			
	Moderna Covid-19 Bivalent Vaccine (Dark Blue Cap) 50MCG/0.5ML Administration - Booster	65.00	8/31/2022	12/31/9999	Added 10/5/2022			ļ
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	150.50	12/8/2021	12/31/9999				

M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	350.00	2/11/2022	12/31/9999		
M0239	Intravenous infusion, bamlanivimab- xxxx, includes infusion and post administration monitoring	309.60	11/10/2020	4/16/2021		
M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	450.00	7/30/2021	12/31/9999		
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	450.00	5/6/2021	12/31/9999		
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	309.60	11/21/2020	5/5/2021		
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	450.00	5/6/2021	8/27/2021		
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	309.60	2/9/2021	5/5/2021		
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	450.00	5/26/2021	12/31/9999		